Multiple sclerosis: new insights and therapeutic progress.
Miller
David
D
Institute of Neurology, University College London, London, UK. d.miller@ion.ucl.ac.uk
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001921:Brain / Q000473:pathology; D002170:Canada / Q000453:epidemiology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000473:pathology; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D020382:Interleukin-18 / Q000172:deficiency; D009103:Multiple Sclerosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D000069442:Natalizumab; D011409:Propylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012737:Sex Factors; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D020382:Interleukin-18; D000069442:Natalizumab; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine